2026-06-14T03:29:53Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/52272024-09-27T10:03:31Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19607
Repisalud
author
Perez-Medina, Carlos
author
Abdel-Atti, Dalya
author
Tang, Jun
author
Zhao, Yiming
author
Fayad, Zahi A
author
Lewis, Jason S.
author
Mulder, Willem J M
author
Reiner, Thomas
funder
Memorial Sloan Kettering Cancer Center
funder
National Institutes of Health (Estados Unidos)
funder
Fundación ProCNIC
2017-10-30T13:15:45Z
2017-10-30T13:15:45Z
2016
Nat Commun. 2016; 7:11838
10.1038/ncomms11838
2041-1723
Nature Communications
27319780
http://hdl.handle.net/20.500.12105/5227
The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictive of therapeutic outcome in individual subjects. In a breast cancer mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter (Zr-89-NRep) allows precise doxorubicin (DOX) quantification. Importantly, Zr-89-NRep uptake also correlates with other types of nanoparticles' tumour accumulation. Zr-89-NRep PET imaging reveals remarkable accumulation heterogeneity independent of tumour size. We subsequently demonstrate that mice with 425 mg kg(-1) DOX accumulation in tumours had significantly better growth inhibition and enhanced survival. This non-invasive imaging tool may be developed into a robust inclusion criterion for patients amenable to nanotherapy.
eng
PEGYLATED LIPOSOMAL DOXORUBICIN
METASTATIC BREAST-CANCER
NAB-PACLITAXEL
OVARIAN-CANCER
DRUG-DELIVERY
TUMOR
NANOMEDICINES
MANAGEMENT
ONCOLOGY
IMPACT
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
journal article
URL
https://repisalud.isciii.es/bitstreams/11cfba5f-0100-4464-abdc-e22421d0bda7/download
File
MD5
c8d8fe67cdb859f616f9074ae5339550
836553
application/pdf
NanoreporterPETPredictsTheEfficacy_2016
URL
https://repisalud.isciii.es/bitstreams/18a192a1-2ee4-482a-a330-3f729fb01b2b/download
File
MD5
0f08525f5f15ecdf3d97bd05b46f40fc
556186
application/pdf
NanoreporterPETPredictsTheEfficacy_2016_Supp
URL
https://repisalud.isciii.es/bitstreams/2b21f42b-7246-4baa-9eda-a5b84c34c8c3/download
File
MD5
7054c9300ee2bbbb5a92e90031abae29
51040
text/plain
NanoreporterPETPredictsTheEfficacy_2016.txt
URL
https://repisalud.isciii.es/bitstreams/5781a6d4-575a-4be0-843c-740b2a8587e6/download
File
MD5
8bbf879f4749baa20c9f4de64260f23f
7405
text/plain
NanoreporterPETPredictsTheEfficacy_2016_Supp.txt